I am here in Davos with someone who really helped the world get out of the
pandemic, helped this event actually happen by helping to create the vaccines
that really rescued us from the Corona virus.
I'm here with Stefan Bansal, who is the CEO of Modena, which really did pioneer
a lot of the MRI and a technology that underpinned the vaccines that we have
all become very accustomed to over the past couple of years.
Thank you so much for being here. Let's start where you announced
yesterday about the RSV. Is this a question of a vaccine for
older people that could potentially protect against the virus in a truck?
Triple D'Amico, whatever people are saying.
What's next? How is this sort of.
But where does this fit in the evolution of the different medications you're
working on? Right.
But first, following me, we are very excited about the ISE vaccine because as
you know, there's no vaccine available today.
And a lot of elderly gets hospitalized or die every year from ISE pre Covid was
never to cause a hospitalization by a respiratory virus.
But what is more exciting for me is this is the mobile platform coming to life.
We've been looking at this technology for 10 years.
We always believed because Amon is an information with a cure, that, if you
will walk in one, you made no scientific sense that you would not walk in many
more. So it's about walking on these a lot of
vaccines or 50 plus vaccines to their respiratory vaccine, but a vaccine
against virus that once in your body stage, your body five of ISE, when I'm
very passionate about CMB, it's all very well known by the public.
But in the US, it's a no number one cause of birth defects more than Down's
syndrome caused by a virus. If mom gets it during a pregnancy and
this, we should stop all those, you know, accidents happening to those
children's over figures. Cancer we announced just before
Christmas some exciting data and skin cancer, grandma.
But we compare ourselves to the best drug to their milk to draw.
And we showed a 44 percent reduction in recurrence or deaths.
We're very happy. We've all.
But now if RTX, we now have inhaled them on air.
It's going to be a lack of kids with multiple sclerosis.
Sorry. We have a cystic fibrosis who cannot
responsibly about DAX drugs. We are talking in cardiology drugs.
So I worry if you go over time, you're going to see a lot of drugs coming from
within here at Davos. One conversation that I've been having
with a lot of people is the concern about the reopening of China.
The positive about how that might juice growth, but the negative of the mass
infections that could potentially produce some sort of mutation in the
existing coronavirus. How do you track that?
You have a sense of what that risk is and what that would look like.
So it's very hard for us to track it because we're not getting the raw data
coming out of China. Our team believed that the risk is not
high, that there is a severe mutations coming out of China.
It's possible because such a large number of people.
But we don't think the risk is high because there's very little resistance
to a virus infecting people because I've ever got a not great vaccine a long time
ago of Haidi Lun get vaccinated and most of them never get infected naturally.
So when the virus infects somebody who doesn't have a resistance that he has,
you know, in the West. And so we think that there is little
reason for a virus to evolve in terms of variants of consoles.
If there is some sort of mutation or another potential pathogen that could
create another pandemic, is there any lesson that has been drawn in terms of
creating a more efficient process? And I recognize that it is pretty
efficient for vaccine standards, for rolling out something, getting it into
the public and preventing 2020 from happening again.
Sure. And we have been working a lot on that
since the pandemic. I was thinking, OK, what could we do
differently next time? And I already hope, of course, next time
doesn't happen for the world and for us. I think that it will happen.
I think it's possible. I mean, if you look at the change in the
climate, there are people on the planet. How would travel, if you talk to
scientific experts say we're going to get another one, it's impossible to know
if it's in four years or 25 years or 100 deals.
But we must. Where are you going to get another one?
And so what's what do we get? The model ISE?
A few things. First, building a global manufacturing
network. Because one of the reasons it took so
long to get vaccine out of the door after they were approved is we had never
sold a product before. So there was no plants ready to make it
other products. Well, today we have more than 2 billion
dollars of annual capacity today in 2019 with zero.
And we're building a plant as we speak in Canada.
Wedding the U.K., one in Australia, one in Kenya.
I hope to be the couple most likely in every continent.
We have plants and we have more capacity.
So that's for any given time to do the clinical studies.
We can make at risk many, many doses for a vaccine.
Think about it. If you are to up into there in six
months to give up a vaccine, which I think we could do next time instead of a
year, we could make a billion dollars. When the vaccine was approved, we
shipped only 20 million doses. That's what we had.
How do you combat the fact that there is this huge anti vaccine movement that
seems to be pretty sticky in terms of its persistence?
Yes. It's something that's really sad to see,
you know, I'm training science. You know, I believe in science and
people not believing, you know, experts like FDA review data, doctors run the
clinical trials. We did not find the clinical trials.
It was run by another company. And he was assessed by independent data
safety net metering committee, like it is always done in the industry to ensure
the highest level of quality of science, because it's a very important business.
You make a product that's going to somebodies body and you're trying to
protect them. You're trying to help anybody,
obviously. And so I think another education, I
think, was as we get on the other side of Covid, that I'm hoping that things
will come down a little bit, as you know, in the US.
Well, it was very political. Unfortunately, what countries outside
the US federal policy goal at an amazing rate of vaccination because it wasn't
political or politicians said once it's approved, will win the trust.
The people, the team of scientists and doctors will prove it and all of us to
get it because we're going to go for this pandemic as a country together.
We need to protect the elderly and we need to open the economy again.
Now, that's what kind of everybody you are saying.
And so people follow. Then the vaccination rates was the
highest in the world. So just to conclude here, I'm wondering
from your perspective, do you think that we could see 20, 20 style lockdowns
again, based on the technology that we have?
How quickly you could potentially ramp up vaccines with regardless of the
pathogen that comes down the pike? So, of course, that would be for the
authorities to decide. As I said, I think we could go down to
maybe, you know, six months from a new virus to product approved next time.
But you still have a few months where you might have a lot of infections and
you might have to protect people at a higher risk, you know, the elderly.
And again, we got lucky on this one, the young children.
We are not, you know, health at the beginning.
In 2020, if you remember, it was mostly the elderly.
Let's talk about the 1918 flu. We are losing as many elderly as
children. So we need to be very careful and to do
the right thing to protect as many people as we can.